Language selection

Search


Private drug plans in Canada : expenditure report, 2018-2023.H82-55/2025E-PDF

"This report provides a comprehensive analysis of trends in prescription drug expenditures from the perspective of Canadian private drug plans. From 2018 to 2023, private pay-direct drug plans experienced a compound annual growth rate of 7.1%, with a significant 12.9% increase in 2023. This growth in 2023 was uneven across its two main components: drug costs (which saw an increase of 14.1%) and dispensing costs (which saw an increase of 4.5%). Over past years, rising expenditures in private plans were consistently driven primarily by significant increases in the use of newer and higher-cost drugs. A comparative analysis with Canadian public drug plans is also included in the report. …"--Executive summary, page iv.

Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.945863&sl=0

Publication information
Department/Agency
  • Canada. Patented Medicine Prices Review Board, issuing body.
TitlePrivate drug plans in Canada : expenditure report, 2018-2023.
Publication typeMonograph
Language[English]
Other language editions[French]
FormatDigital text
Electronic document
Note(s)
  • Issued also in French under title: Régimes privés d'assurance-médicaments au Canada : rapport sur les dépenses, 2018-2023.
  • On cover: NPDUIS, National Prescription Drug Utilization Information System.
  • Includes bibliographical references.
Publishing information
  • Ottawa, ON : Patented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, February 2025.
  • ©2025
Description1 online resource (vi pages, 1 unnumbered page, 41 pages) : colour illustrations
ISBN9780660747705
Catalogue number
  • H82-55/2025E-PDF
Subject terms
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.

Page details